Search clinical trials for: Pneumococcal vaccines

Total 4139 results

Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.

Influenza Disease

Italy
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.

Influenza

Italy
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.

Pneumococcal Infections

France
University of Michigan

Completed

Memory for Flu Facts and Myths and Effects on Vaccine Intentions

Influenza Vaccines

United States, Canada
National Center for Research Resources (NCRR)
Northwestern University

Unknown

Study of Novel Types of Familial Diabetes Insipidus

Diabetes Insipidus
Catalan Institute of Health

Completed

Safety of the Intramuscular Route of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation Therapy

Influenza

Spain
Chiron Corporation

Unknown

Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine

Meningococcal Disease; Meningococcal Meningitis

United Kingdom
French National Agency for Research on AIDS and...
Aventis Pharmaceuticals

Terminated

Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers

HIV Infections

France
Johns Hopkins Bloomberg School of Public Health

Completed

AMR of Streptococcus Pneumoniae Carriage Strains

Infection
Centers for Disease Control and Prevention
Kaiser Permanente

Completed

Racial Disparities in Pneumococcal Vaccination in Managed Care

Pneumococcal Disease Prevention

United States
University Of Perugia

Completed

Influenza Vaccination and Oral Anticoagulant Therapy

Influenza Vaccines | Anticoagulants

Italy
French National Agency for Research on AIDS and...
Aventis Pharmaceuticals

Terminated

HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection

HIV Infection
Daiichi Sankyo, Inc.

Completed

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

Hypertension

United States
Centers for Disease Control and Prevention
National Institute of Allergy and Infectious Diseases (NIAID); Alaska Native... and other collaborators

Completed

Study to Eliminate Hib Carriage in Rural Alaska Native Villages

Haemophilus Influenzae Type B | Carrier State

United States
Cell Genesys

Completed

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)

Prostate Cancer
Cell Genesys

Completed

Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)

Prostate Cancer
National Institute of Allergy and Infectious Diseases...
Istituto Superiore di Sanità

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines

Pertussis
National Institute of Allergy and Infectious Diseases...
National Bacteriological Laboratory

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines

Pertussis
Walter Reed Army Institute of Research (WRAIR)

Unknown

HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Center for Research Resources (NCRR)

Completed

Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

United States
National Institute of Allergy and Infectious Diseases...
United Biomedical

Completed

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

An HIV Vaccine Preparedness Study

HIV Infections

United States
The Immune Response Corporation

Completed

An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml

HIV Infections

United States
Walter Reed Army Institute of Research (WRAIR)

Completed

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

HIV Infections | HIV Seronegativity

United States
United Biomedical

Completed

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

HIV Infections

United States
United Biomedical

Completed

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

HIV Infections

United States
The Immune Response Corporation

Completed

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

HIV Infections

United States
VaxGen

Completed

A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

HIV Infections

United States
Genentech, Inc.

Completed

A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers

HIV Infections

United States
The Immune Response Corporation

Completed

An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

HIV Infections

United States
Chiron Corporation

Completed

A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults

HIV Infections | HIV Seronegativity

United States
Wyeth-Lederle Vaccines

Completed

A Study of GENEVAX-HIV, a Possible Vaccine

HIV Infections | HIV Seronegativity

United States
Wyeth-Lederle Vaccines

Completed

Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.

Completed

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

HIV Infections

United States
Apollon

Completed

A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients

HIV Infections

United States
VaxGen

Completed

Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection

HIV Infections | HIV Seronegativity

United States, Canada, Netherlands, Puerto Rico

3

Subscribe